EFFECT OF FREQUENT GENERIC IMATINIB SWITCHING ON TREATMENT RESPONSE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA

EFFECT OF FREQUENT GENERIC IMATINIB SWITCHING ON TREATMENT RESPONSE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA

Objective: The aim of this study was to evaluate the effect of switching one or more generic imatinibs during treatment on outcomes in patients with chronic phase chronic myeloid leukemia.. Case Report: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm associated with the Philadelphia...

Full description

Saved in:

Bibliographic Details
Main Authors:	Murat Çınarsoy, Buğra Sağlam
Format:	Article
Language:	English
Published:	Elsevier 2024-12-01
Series:	Hematology, Transfusion and Cell Therapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2531137924028839
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The efficacy of generic imatinib in patients with chronic myeloid leukemia: A single centre experience
by: Urošević Ivana, et al.
Published: (2021-01-01)

Treatment efficacy of chronic myeloid leukemia with imatinib in clinical practice
by: A. K. Golenkov, et al.
Published: (2014-07-01)

Mutation status of refractory to imatinib patients with chronic myeloid leukemia
by: E. G. Ovsyannikova, et al.
Published: (2014-07-01)

Chronic myeloid leukemia — before and after imatinib (First part)
by: E. G. Lomaia, et al.
Published: (2022-11-01)

Chronic myeloid leukemia — before and after imatinib (part II)
by: E. G. Lomaia, et al.
Published: (2022-11-01)

Chronic myeloid leukemia — before and after imatinib (Third part)
by: E. G. Lomaia, et al.
Published: (2022-11-01)

Factors associated with achievement and durability of cytogenetic response in patients with chronic myeloid leukemia treated with imatinib
by: Ćojbašić Irena, et al.
Published: (2011-01-01)

BCR-ABL gene amplification in patients with chronic myeloid leukemia and imatinib resistance
by: S. I. Kutzev, et al.
Published: (2022-11-01)

Dynamics of Chronic Myeloid Leukemia Under Imatinib Treatment: A Study of Resistance Development
by: Irina Badralexi, et al.
Published: (2024-12-01)

An uneventful pregnancy and delivery, in a case with chronic myeloid leukemia on imatinib
by: Jovita Martin, et al.
Published: (2011-01-01)

Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia.
by: Kibum Kim, et al.
Published: (2019-01-01)

Long-term treatment outcome in chronic myeloid leukemia patients in accelerated phase treated with imatinib (glevec®)
by: L. A. Antipova, et al.
Published: (2022-11-01)

Bilateral mandibular osteonecrosis associated with imatinib monotherapy for a patient with chronic myeloid leukemia
by: Yasuharu Yajima, et al.
Published: (2025-04-01)

Chronic myeloid leukemia treatment with Imatinib: An experience from a private tertiary care hospital
by: D C Doval, et al.
Published: (2013-01-01)

B-Cell Chronic Lymphocytic Leukemia with 11q22.3 Rearrangement in Patient with Chronic Myeloid Leukemia Treated with Imatinib
by: Krzysztof Lewandowski, et al.
Published: (2016-01-01)

Effectiveness of three prognostic scoring systems in predicting the response and outcome in pediatric chronic myeloid leukemia chronic phase on frontline imatinib
by: Ranga Raman Ganta, et al.
Published: (2017-01-01)

Incidence of BCR-ABL transcript variants in patients with chronic myeloid leukemia: Their correlation with presenting features, risk scores and response to treatment with imatinib mesylate
by: Pratik Deb, et al.
Published: (2014-01-01)

Imatinib Adherence and Persistence in Patients with Chronic Myeloid Leukemia in Belgium: Evidence from Real-World Data
by: Michiels S, et al.
Published: (2024-09-01)

LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE
by: Michelina Santopietro, et al.
Published: (2011-01-01)

Profile of pediatric chronic myeloid leukemia in the era of imatinib: A study from South India
by: Catherene Bernard, et al.
Published: (2019-01-01)

Chronic myeloid leukemia in the Imatinib era - Compilation of Indian data from 22 centers involving 8115 patients
by: Purvish Parikh, et al.
Published: (2013-01-01)

DOWNREGULATION OF STEAROYL-COA DESATURASE 1 (SCD-1) PROMOTES RESISTANCE TO IMATINIB IN CHRONIC MYELOID LEUKEMIA
by: Buket Altinok Gunes, et al.
Published: (2023-01-01)

Early Molecular Response to Imatinib First-Line Therapy and Predictive Factors of Poor Outcomes for Chronic Myeloid Leukemia Patients in Côte d’Ivoire
by: Kouassi Gustave Koffi, et al.
Published: (2024-01-01)

Pro-Inflammatory Cytokines in Patients With Chronic Phase-Chronic Myeloid Leukaemia Treated With Imatinib: Any Role in the Monitoring of Treatment Response?
by: Kehinde A. Taiwo, et al.
Published: (2025-06-01)

Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data
by: Petra Belohlavkova, et al.
Published: (2024-09-01)

Pregnancy and Accelerated Phase of Myeloid Chronic Leukemia Treated with Imatinib: A Case Report from a Developing Country
by: Lydie Ocini Ngolet, et al.
Published: (2016-01-01)

Serum Levels of Advanced Oxidation Protein Products and some Liver Function Markers in Chronic Myeloid Leukemia-Chronic Phase Patients Receiving Imatinib or Nilotinib
by: Ikhlas Khammas, et al.
Published: (2025-06-01)

The role of mutation testing in patients with chronic myeloid leukemia in chronic phase after imatinib failure and their outcomes after treatment modification: Single-institutional experience over 13 years
by: Puligundla Krishna Chaitanya, et al.
Published: (2017-01-01)

Lack of Association between C1236T, G2677T/A and C3435T Variants of the ABCB1 Gene and Imatinib Response in Iranian Chronic Myeloid Leukemia Patients
by: Maedeh Khosravi, et al.
Published: (2021-05-01)

Long-Term Safety and Efficacy of Imatinib in Chronic Myeloid Leukemia: Real-World Evidence from a Single-Center Study
by: İsmail Can Kendir, et al.
Published: (2025-06-01)

ZFAS1/STAT3 axis modulates imatinib resistance of chronic myeloid leukemia cells through glucose metabolism reprogramming
by: Lan Yang, et al.
Published: (2025-07-01)

Chiglitazar diminishes the warburg effect through PPARγ/mTOR/PKM2 and increases the sensitivity of imatinib in chronic myeloid leukemia
by: Hongpeng Duan, et al.
Published: (2024-12-01)

Effect of standardized Aronia Melanocarpa extract on oxidative stress and antioxidant status in patient with cronic myeloid leukemia treated with imatinib
by: Bojan Labachevski, et al.
Published: (2024-12-01)

Molecular, Cytogenetic, and Hematological Monitoring and Response to Treatment for Chronic Myeloid Leukemia Patients
by: Noor Al-Huda Bahar, et al.
Published: (2024-12-01)

TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA
by: Michele Baccarani, et al.
Published: (2014-01-01)

The Effect of Imatinib Mesylate for Newly Diagnosed Philadelphia Chromosome-Positive, Chronic-Phase Myeloid Leukemia in Sub-Saharan African Patients: The Experience of Côte d'Ivoire
by: K. G. Koffi, et al.
Published: (2010-01-01)

Quality of life, symptom profile and clinical efficacy of second-line treatment with dasatinib in patients with imatinib-resistant or -intolerant chronic myeloid leukemia: results of 2-year follow-up
by: T. I. Ionova, et al.
Published: (2015-10-01)

Intravitreal Bevacizumab and Triamcinolone for Treatment of Cystoid Macular Oedema Associated with Chronic Myeloid Leukaemia and Imatinib Therapy
by: Eric K. Newcott, et al.
Published: (2015-01-01)

Impact of non-coding RNAs on resistance to imatinib in chronic myelogenous leukemia
by: Fatemeh Ensafi Talemi, et al.
Published: (2025-01-01)

Metabolomic Profiling and Bioanalysis of Chronic Myeloid Leukemia: Identifying Biomarkers for Treatment Response and Disease Monitoring
by: Selim Sayın, et al.
Published: (2025-06-01)